Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 112Gynecologic 5Breast 5Thoracic 3Genitourinary 3CNS 3Sarcoma 2Head & Neck 2Dermatologic 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Nasopharyngeal Carcinoma 71Nasopharyngeal Neoplasms 25Head and Neck Neoplasms 25Squamous Cell Carcinoma of Head and Neck 18Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 11Recurrence 9Salivary Gland Neoplasms 7Ovarian Neoplasms 7Stomach Neoplasms 6Pancreatic Neoplasms 6Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Neoplasms 5Melanoma 5Colorectal Neoplasms 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Sarcoma 4Lung Neoplasms 4Esophageal Neoplasms 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Laryngeal Diseases 3Epstein-Barr Virus Infections 3Colonic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Osteosarcoma 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2

Interventions

pembrolizumab 9Nivolumab 4Magnetic Resonance Spectroscopy 3spartalizumab 2Ipilimumab 2Gemcitabine 2Fluorodeoxyglucose F18 2FAPI-46 2Drug Therapy 2Cisplatin 2zenocutuzumab 1venetoclax 1ulixertinib 1trametinib 1tislelizumab 1seribantumab 1rovalpituzumab tesirine 1pazopanib 1neratinib 1margetuximab 1lenvatinib 1entrectinib 1durvalumab 1cobimetinib 1cemiplimab 1budigalimab 1bemarituzumab 1atezolizumab 1alectinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Gemcitabine × Head & Neck × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡